Advertisement
Singapore markets close in 4 hours 37 minutes

  • Straits Times Index

    3,168.93
    -18.73 (-0.59%)
     

  • Nikkei

    37,169.48
    -910.22 (-2.39%)
     

  • Hang Seng

    16,184.02
    -201.85 (-1.23%)
     

  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     

  • Bitcoin USD

    62,316.64
    +474.82 (+0.77%)
     

  • CMC Crypto 200

    1,287.15
    +401.61 (+44.14%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Gold

    2,404.30
    +6.30 (+0.26%)
     

  • Crude Oil

    84.83
    +2.10 (+2.54%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • FTSE Bursa Malaysia

    1,550.49
    +5.73 (+0.37%)
     

  • Jakarta Composite Index

    7,050.80
    -116.01 (-1.62%)
     

  • PSE Index

    6,411.73
    -111.46 (-1.71%)
     

Why ChemoCentryx Stock Tanked in 2021

George Budwell, The Motley Fool
·2-min read
Why ChemoCentryx Stock Tanked in 2021

Shares of ChemoCentryx (NASDAQ: CCXI), a mid-cap biopharmaceutical company, fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence. ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels. Although the Food and Drug Administration (FDA) ultimately approved Tavneos on Oct. 8, 2021, the drug's fate was far from certain due to a mixed advisory committee (adcom) meeting earlier in the year.

Continue reading